Biological and clinical evidence for somatic mutations in <i>BRCA1</i> and <i>BRCA2</i> as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance settingBrian Dougherty, J. Carl Barrett, Roman Yelensky et al.|Oncotarget|2017Cited by 99
Abstract 611: Exploratory analyses suggest ovarian tumors with somatic or germline loss of function mutations in <i>BRCA1</i> or <i>BRCA2</i> are biologically similar and sensitive to PARP inhibitionBrian Dougherty, J. Carl Barrett, Zhongwu Lai et al.|Cancer Research|2015Cited by 4
Analysis of candidate homologous repair deficiency genes in a clinical trial of olaparib in patients (pts) with platinum-sensitive, relapsed serous ovarian cancer (PSR SOC).Brian Dougherty, J. Carl Barrett, James Sun et al.|Journal of Clinical Oncology|2014Cited by 3